Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 10/20 | 0.53 |
| ▸ | FNTB | P49356 | 10/20 | 0.53 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.53 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5093000 | 0.87 | FNTA (0.54) | FNTAFNTBPGGT1B | |
| SCHEMBL5099548 | 0.80 | PLAU (0.46) | FNTAFNTBPGGT1BPLAUTP53 | |
| SCHEMBL24017185 | 0.79 | TP53 (0.48) | FNTAFNTBPGGT1BPLAUTP53 | |
| SCHEMBL5091221 | 0.79 | FNTA (0.50) | FNTAFNTBPGGT1B | |
| SCHEMBL30870707 | 0.79 | PLAU (0.46) | FNTAFNTBPGGT1BCYP1A2CYP3A4 | |
| SCHEMBL5091260 | 0.79 | PLAU (0.48) | FNTAFNTBPGGT1BPLAU | |
| SCHEMBL28854331 | 0.78 | HTR7 (0.51) | CYP1A2CYP3A4CYP2D6TSHRMAPK1 | |
| SCHEMBL5098820 | 0.77 | ADORA2A (0.47) | FNTAFNTBPGGT1BPLAUTP53 | |
| SCHEMBL7446928 | 0.76 | PGR (0.55) | CYP1A2CYP3A4CYP2D6CYP2C19CLK4 | |
| SCHEMBL7629793 | 0.75 | PGR (0.57) | CYP1A2CYP3A4CYP2D6CYP2C19PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323570-B2 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES (US) | 2008-01-29 | — | — | US | disclosed |
| US-7211595-B2 | Farnesyltransferase inhibitors | ABBOTT LABORATORIES (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | ABBVIE INC. | 2006-11-23 | — | — | US | disclosed |
| EP-1339695-B1 | FARNESYLTRANSFERASE INHIBITORS | ABBOTT LAB (US) | 2006-04-19 | — | — | EP | disclosed |
| US-20030087940-A1 | Farnesyltransferase inhibitors | ABBVIE INC. | 2003-05-08 | — | — | US | disclosed |
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115640-A1 | Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents | FNTB, FNTA, ACAT2 | FNTA 2/4885FNTB 1/4885PGGT1B 28/4885 |
| US-20060264476-A1 | Farnesyltransferase Inhibitors | FNTB, FNTA, FDPS | FNTA 2/4885FNTB 1/4885PGGT1B 16/4885 |
| US-20030087940-A1 | Farnesyltransferase inhibitors | FNTB, FNTA, FDPS | FNTA 2/4885FNTB 1/4885PGGT1B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.